CN109464570B - 一种首荟通便胶囊制备工艺 - Google Patents
一种首荟通便胶囊制备工艺 Download PDFInfo
- Publication number
- CN109464570B CN109464570B CN201811404355.1A CN201811404355A CN109464570B CN 109464570 B CN109464570 B CN 109464570B CN 201811404355 A CN201811404355 A CN 201811404355A CN 109464570 B CN109464570 B CN 109464570B
- Authority
- CN
- China
- Prior art keywords
- parts
- aloe
- ethanol
- mixing
- drying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000011399 aloe vera Nutrition 0.000 title claims abstract description 89
- 241001116389 Aloe Species 0.000 title claims abstract description 87
- 239000002775 capsule Substances 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title claims abstract description 51
- 240000001341 Reynoutria japonica Species 0.000 title claims abstract description 19
- 235000018167 Reynoutria japonica Nutrition 0.000 title claims abstract description 19
- 230000002040 relaxant effect Effects 0.000 title claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 59
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 31
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 31
- 235000008434 ginseng Nutrition 0.000 claims abstract description 31
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 20
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 20
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 20
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 20
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 18
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 18
- 241000132012 Atractylodes Species 0.000 claims abstract description 17
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 17
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 17
- 108010010803 Gelatin Proteins 0.000 claims abstract description 16
- 229920000159 gelatin Polymers 0.000 claims abstract description 16
- 239000008273 gelatin Substances 0.000 claims abstract description 16
- 235000019322 gelatine Nutrition 0.000 claims abstract description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 201
- 238000002156 mixing Methods 0.000 claims description 76
- 238000001035 drying Methods 0.000 claims description 63
- 239000000843 powder Substances 0.000 claims description 56
- 238000007873 sieving Methods 0.000 claims description 51
- 239000000341 volatile oil Substances 0.000 claims description 48
- 239000000243 solution Substances 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 37
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 36
- 239000000706 filtrate Substances 0.000 claims description 35
- 238000001914 filtration Methods 0.000 claims description 32
- 241000208340 Araliaceae Species 0.000 claims description 30
- 239000008187 granular material Substances 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 26
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 25
- 239000000600 sorbitol Substances 0.000 claims description 25
- 239000000284 extract Substances 0.000 claims description 23
- 238000009835 boiling Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 17
- 238000000746 purification Methods 0.000 claims description 17
- 108010052008 colla corii asini Proteins 0.000 claims description 16
- 238000005194 fractionation Methods 0.000 claims description 16
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 15
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical group [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 15
- 235000013539 calcium stearate Nutrition 0.000 claims description 15
- 239000008116 calcium stearate Substances 0.000 claims description 15
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 15
- 238000000227 grinding Methods 0.000 claims description 15
- 238000002791 soaking Methods 0.000 claims description 15
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 14
- 238000010298 pulverizing process Methods 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 14
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 14
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 14
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 13
- 238000011049 filling Methods 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 235000014104 aloe vera supplement Nutrition 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 10
- 238000002844 melting Methods 0.000 claims description 10
- 230000008018 melting Effects 0.000 claims description 10
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 244000241838 Lycium barbarum Species 0.000 claims description 3
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 3
- 235000015468 Lycium chinense Nutrition 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 claims 6
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 16
- 239000000463 material Substances 0.000 abstract description 7
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000010415 tropism Effects 0.000 description 8
- 206010010774 Constipation Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000008141 laxative Substances 0.000 description 7
- 230000002475 laxative effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 241001289529 Fallopia multiflora Species 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- JAYVHSBYKLLDJC-DSNJPTTOSA-N (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(O)C=C(O)C=C1\C=C\C1=CC=C(O)C=C1 JAYVHSBYKLLDJC-DSNJPTTOSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- -1 2, 3, 5, 4 ' -tetrahydroxystilbene-2-O- Chemical class 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000035568 catharsis Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010000242 Abortion threatened Diseases 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005985 Threatened Abortion Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000018997 giddiness Diseases 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101100361281 Caenorhabditis elegans rpm-1 gene Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药领域,具体公开了一种首荟通便胶囊及其制备工艺改进,首荟通便由下列中药组分制成:阿胶75重量份、芦荟160重量份、何首乌120重量份、决明子140重量份、枸杞子75重量份、白术50重量份、枳实120重量份、人参50重量份。本发明中通过采用针对不同中药采用不用的制备工艺,保证有效成分的含量,同时筛选了现有的辅料以及用量比例,对首荟通便的制剂工艺进行提升,优选的制备工艺,在含水量、崩解时限以及溶出度等各项性能指标均符合中国药典的要求,适合工业化大生产。
Description
技术领域
本发明涉及首荟通便胶囊制备工艺,属于中药领域。
背景技术
首荟通便胶囊,精选道地药材,是通便排毒、减肥降脂的国家专利组方。全方由8味中药材组成,针对性治疗功能性便秘,中医辨证属气阴两虚兼毒邪内蕴证者,症见便秘,腹胀,口燥咽干,神疲乏力,五心烦热,舌质红嫩或淡,舌苔白或白腻,脉沉细或滑数。具有泻浊通便、养阴益气的功效,全面改善胃肠功能。
中国专利CN100453105C公开了一种具有通便排毒、减肥降脂功能的组合物及制备方法,产品为“首荟通便胶囊”,现已获得生产批准。该产品是由何首乌、芦荟、决明子、枸杞子、阿胶、人参、白术、枳实八味中药组方,疗效确切,起效快,对毒邪内蕴、阴液亏虚所致的便秘具有良好的治疗作用。中国专利CN106124685A公开了一种首荟通便胶囊的质量检测方法,中国专利CN106123496A公开了一种首荟通便浸膏的干燥方法。
在后续研发过程中,发现首荟通便胶囊的性能虽然达到药典的标准,但是仍然存在具有可提升的空间,例如含量水可进一步降低,崩解时限也可以进一步缩减。
发明内容
本发明通过优选辅料以及控制关键技术点再次对首荟通便胶囊的制备工艺进行技术升级,最终所获得首荟通便胶囊以满足临床需要前提下,各项指标均优于药典标准。
为了实现上述目的,本发明采取的技术方案为:
本发明所述的何首乌、人参、决明子、芦荟、枳实、枸杞子、阿胶和白术中药组合物的原料主要包括按重量份数计的以下组分:
阿胶20-180重量份、芦荟40-400重量份、决明子40-250重量份、何首乌25-400重量份、枸杞子30-100重量份、白术10-80重量份、枳实40-280重量份、人参20-100重量份。
进一步优选为:阿胶30-150重量份、芦荟50-200重量份、决明子60-160重量份、何首乌40-200重量份、枸杞子50-80重量份、白术30-60重量份、枳实60-160重量份、人参40-80重量份。
更进一步优选为:阿胶75重量份、芦荟160重量份、何首乌120重量份、决明子140重量份、枸杞子75重量份、白术50重量份、枳实120重量份、人参50重量份。
本发明的治疗慢性肠炎的中药组合物中所使用的各味中药材的功用如下:
何首乌:性味苦、甘、涩,温。
归经:归肝、心、肾经。
功能主治:解毒,消痈,润肠通便。用于瘰疠疮痈,风疹瘙痒,肠燥便秘;高血脂。
芦荟:性味苦,寒。
归经:归肝、胃、大肠经。
功能主治:清肝热,通便。用于便秘,小儿疳积,惊风;外治湿癣。
枸杞子:性味甘,平。
归经:归肝、肾经。
功能主治:滋补肝肾,益精明目。用于虚劳精亏,腰膝酸痛,眩晕耳鸣,内热消渴,血虚萎黄,目昏不明。
白术:性味苦、甘,温。
归经:归脾、胃经。
功能主治:健脾益气,燥湿利水,止汗,安胎。用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。土白术健脾,和胃,安胎。用于脾虚食少,泄泻便溏,胎动不安。
枳实:性味苦、辛、酸,温。
归经:归脾、胃经。
功能主治:破气消积,化痰散痞。用于积滞内停,痞满胀痛,泻痢后重,大便不通,痰滞气阻胸痹,结胸;胃下垂,脱肛,子宫脱垂。
人参:性味甘、微苦,平。
归经:归脾、肺、心经。
功能主治:大补元气,复脉固脱,补脾益肺,生津,安神。用于体虚欲脱,肢冷脉微,脾虚食少,肺虚喘咳,津伤口渴,内热消渴,久病虚羸,惊悸失眠,阳痿宫冷;心力衰竭,心原性休克。
决明子:性味咸苦;平凉;无毒。
归经:肝;胆;肾经。
功能主治:祛风清热,解毒利湿。主风热感冒,流感,急性结膜炎,湿热黄疸,急慢性肾炎,带下,瘰疬,疮痈疖肿,乳腺炎。
阿胶:性味甘,平。
归经:归肺、肝、肾经。
功能主治:补血滋阴,润燥,止血。用于血虚萎黄,眩晕心悸,肌痿无力,心烦不眠,虚风内动,肺燥咳嗽,劳嗽咯血,吐血尿血,便血崩漏,妊娠胎漏。
本发明提供了首荟通便胶囊的制备方法,其特征在于,包括以下步骤:
a、分提、纯化工艺
1)、人参、阿胶真空状态下研磨成细粉;
2)、制备枳实、决明子和白术的滤液;
3)、制备何首乌、芦荟包合物,药渣及水溶液备用;
4)、步骤3)的药渣及水溶液与枸杞子加水煎煮,得煎液;
5)、步骤2)的滤液及步骤4)中所得煎液合并,制备成细粉;
6)、将步骤5)和步骤1)中所得细粉与步骤3)中所得包合物混匀,即得首荟通便提取物;
b、制剂工艺
1)聚乙二醇加热熔融,加入首荟通便提取物拌匀,干燥;
2)向步骤1)中加入填充剂、粘合剂、润滑剂,制粒,干燥,并填充于胶囊壳中,制得首荟通便胶囊。
所述的分提、纯化工艺步骤2)制备工艺为:枳实、决明子和白术粉碎并过80目筛,加65-75%的乙醇回流提取两次,合并滤液,备用。
所述的分提、纯化工艺步骤3)包合物的制备过程为:何首乌、芦荟加水浸泡0.5-5小时,用挥发油提取器提取挥发油,制备加入环糊精制备包合物,药渣及水溶液备用。
所述的分提、纯化工艺步骤5)的制备过程为:将步骤2)的滤液及4)中所得煎液合并,滤过,浓缩至相对密度为1.01-1.05的清膏,加乙醇使得醇的含量50-70%,静止10-20小时,滤过,减压回收乙醇并浓缩至相对密度的1.15-1.35,得稠膏,真空度-0.08MPa--0.10Mpa,干燥温度85℃-95℃干燥,真空状态下粉碎过80目筛,得细粉。
所述的聚乙二醇为的平均分子量大于600;优选为聚乙二醇4000。
所述填充剂为乳糖、甘露醇、蔗糖、淀粉、预胶化淀粉、葡萄糖、山梨醇、环糊精中的一种或几种,优选为山梨醇和环糊精的混合物;所述的粘合剂为羧甲基纤维素钠、交联羧甲基纤维素钠、甲基纤维素钠、羟丙甲纤维素的醇溶液中的一种;所述的润滑剂为硬脂酸镁、硬脂酸钙、滑石粉中的一种。
所述的环糊精为羟丙基-β-环糊精,所述的粘合剂为羧甲基纤维素钠5%的乙醇溶液,所述的润滑剂为硬脂酸钙。
所述的山梨醇和羟丙基-β-环糊精的重量用量比为0.5-2.5∶3,优选的是,所述的山梨醇和羟丙基-β-环糊精的重量用量比为1.5∶3。
进一步地,一种首荟通便胶囊的制备工艺,包含如下步骤:
a、分提、纯化工艺
1)、将人参、阿胶真空状态下研磨成细粉,过80目筛,备用;
2)、枳实、决明子和白术粉碎并过80目筛,加65-75%的乙醇回流提取两次,合并滤液,备用;
3)、何首乌、芦荟加水浸泡0.5-5小时,用挥发油提取器提取挥发油,药渣及水溶液备用;
4)、取步骤3)中挥发油并用无水硫酸钠干燥,再用处方量的羟丙基-β-环糊精包合,制得包合物;
5)、取步骤3)中蒸馏后的药渣及水溶液与枸杞子加水煎煮二次,将两次所得的煎液混合,备用;
6)、将步骤2)的滤液及步骤5)中所得煎液合并,滤过,浓缩至相对密度为1.01-1.05的清膏,加乙醇使得醇的含量50-70%,静止10-20小时,滤过,减压回收乙醇并浓缩至相对密度的1.15-1.35,得稠膏,真空度-0.08MPa--0.10Mpa,干燥温度85℃-95℃干燥,真空状态下粉碎过80目筛,得细粉;
7)、将6)中所得细粉、1)中所得细粉、4)中所得挥发油包合物混匀,即得首荟通便提取物,备用;
b、制剂工艺
1)聚乙二醇加热熔融,加入处方量的首荟通便提取物拌均匀,40-60℃干燥;
2)测定1)的重量,加入其重量5-15%的山梨醇和羟丙基-β-环糊精的混合物,其中混合物中山梨醇和羟丙基-β-环糊精的重量比为0.5-2.5∶3;再加入适量5%的羧甲基纤维素钠乙醇溶液制软材,过18目筛制粒,45~55℃沸腾干燥,备用;
3)向步骤3)中加入适量的硬脂酸钙混合均匀,16目筛整粒,得到干燥的颗粒,备用;
4)将步骤4)干燥的颗粒填充于胶囊壳中,制得首荟通便胶囊。
更进一步地,一种首荟通便胶囊的制备工艺,包含如下步骤:
a、分提、纯化工艺
1)、将人参、阿胶真空状态下研磨成细粉,过80目筛,备用;
2)、枳实、决明子和白术粉碎并过80目筛,加75%的乙醇回流提取两次,合并滤液,备用;
3)、何首乌、芦荟加水浸泡2小时,用挥发油提取器提取挥发油,药渣及水溶液备用;
4)、取3)中挥发油并用无水硫酸钠干燥,再用处方量的羟丙基-β-环糊精包合,制得包合物;
5)、取3)中蒸馏后的药渣及水溶液与枸杞子加水武火煮沸之后,文火1.5小时,煎煮二次,将两次所得的煎液混合;
6)、将2)的滤液及5)中所得煎液合并,滤过,浓缩至相对密度为1.03的清膏,加乙醇使得醇的含量60%,静止15小时,滤过,减压回收乙醇并浓缩至相对密度的1.25,得稠膏,真空度-0.08MPa--0.10Mpa,干燥温度85℃-95℃干燥,真空状态下粉碎成细粉,过80目筛;
7)、将1)中所得细粉、4)中所得挥发油包合物、6)中所得细粉混匀,即得首荟通便提取物,备用;
b、制剂工艺
1)聚乙二醇加热熔融,加入处方量的首荟通便提取物拌均匀,50℃干燥;
2)测定1)的重量,加入其重量10%的山梨醇和羟丙基-β-环糊精的混合物,其中混合物中山梨醇和羟丙基-β-环糊精的重量比为1.5∶3;再加入适量的5%羧甲基纤维素钠乙醇溶液制软材,过18目筛制粒,50℃沸腾干燥,备用;
3)向步骤3)中加入适量的硬脂酸钙混合均匀,16目筛整粒,得到干燥的颗粒,备用;
4)将步骤4)干燥的颗粒填充于胶囊壳中,制得首荟通便胶囊。
与现有技术相比,本发明预料不到的有益效果为:
本发明中通过采用针对不同中药采用不用的提取制备工艺,保证有效成分的含量,同时筛选了现有的辅料以及用量比例,对首荟通便胶囊的制剂工艺进行提升,在含水量、崩解时限以及溶出度等各项性能指标均符合中国药典的要求,适合工业化大生产。
本发明所述的首荟通便胶囊,崩解效果较好,能在规定的时间内崩解完成(药典规定30分钟崩解完全),在长期稳定试验中,优于原始工艺。
在溶出度测试试验中,本发明实施例1-4均达到了80%以上的溶出,20min内均达到了90%以上的溶出,尤其是实施例1优于其他实施例以及对照组。原始工艺在15min也仅有71.57%,可见,与传统的首荟通便胶囊相比较,本发明首荟通便胶囊制剂溶出迅速、全面,说明所制产品的体外溶出效果良好。
具体实施方式
实施例1:一种首荟通便胶囊,含量及制备工艺如下:
阿胶75重量份、芦荟160重量份、何首乌120重量份、决明子140重量份、枸杞子75重量份、白术50重量份、枳实120重量份、人参50重量份。
制备工艺如下:
a、分提、纯化工艺
1)、将人参、阿胶真空状态下研磨成细粉,过80目筛,备用;
2)、枳实、决明子和白术粉碎并过80目筛,加75%的乙醇回流提取两次,合并滤液,备用;
3)、何首乌、芦荟加水浸泡2小时,用挥发油提取器提取挥发油,药渣及水溶液备用;
4)、取步骤3)中挥发油并用无水硫酸钠干燥,再用处方量的羟丙基-β-环糊精包合,制得包合物;
5)、取步骤3)中蒸馏后的药渣及水溶液与枸杞子加水武火煮沸之后,文火1.5小时,煎煮二次,将两次所得的煎液混合;
6)、将步骤2)的滤液及5步骤)中所得煎液合并,滤过,浓缩至相对密度为1.03的清膏,加乙醇使得醇的含量60%,静止15小时,滤过,减压回收乙醇并浓缩至相对密度的1.25,得稠膏,真空度-0.08MPa--0.10Mpa,干燥温度85℃-95℃干燥,真空状态下粉碎过80目筛,得细粉;
7)、将步骤1)中所得细粉、步骤4)中所得挥发油包合物、步骤6)中所得细粉混匀,即得首荟通便提取物,备用;
b、制剂工艺
1)聚乙二醇4000加热熔融,加入处方量的首荟通便提取物拌均匀,50℃干燥;
2)测定1)的重量,加入其重量10%的山梨醇和羟丙基-β-环糊精的混合物,其中混合物中山梨醇和羟丙基-β-环糊精的重量比为1∶2;再加入适量的5%羧甲基纤维素钠乙醇溶液制软材,过18目筛制粒,50℃沸腾干燥,备用;
3)向步骤3)中加入适量的硬脂酸钙混合均匀,16目筛整粒,得到干燥的颗粒,备用;
4)将步骤4)干燥的颗粒填充于胶囊壳中,制得首荟通便胶囊。
实施例2:一种首荟通便胶囊,含量及制备工艺如下:
阿胶75重量份、芦荟160重量份、何首乌120重量份、决明子140重量份、枸杞子75重量份、白术50重量份、枳实120重量份、人参50重量份。
制备工艺如下:
a、分提、纯化工艺
1)、将人参、阿胶真空状态下研磨成细粉,过80目筛,备用;
2)、枳实、决明子和白术粉碎并过80目筛,加65%的乙醇回流提取两次,合并滤液,备用;
3)、何首乌、芦荟加水浸泡0.5小时,用挥发油提取器提取挥发油,药渣及水溶液备用;
4)、取步骤3)中挥发油并用无水硫酸钠干燥,再用处方量的羟丙基-β-环糊精包合,制得包合物;
5)、取3)中蒸馏后的药渣及水溶液与枸杞子加水武火煮沸之后,文火1.5小时,煎煮二次,将两次所得的煎液混合;
6)、将步骤2)的滤液及步骤5)中所得煎液合并,滤过,浓缩至相对密度为1.01的清膏,加乙醇使得醇的含量50%,静止10小时,滤过,减压回收乙醇并浓缩至相对密度的1.15,得稠膏,真空度-0.08MPa,干燥温度85℃干燥,真空状态下粉碎过80目筛,得细粉;
7)、将步骤6)中所得细粉、步骤1)中所得细粉、步骤4)中所得挥发油包合物混匀,即得首荟通便提取物,备用;
b、制剂工艺
1)聚乙二醇600加热熔融,加入处方量的首荟通便提取物拌均匀,40℃干燥;
2)测定1)的重量,加入其重量5%的山梨醇和羟丙基-β-环糊精的混合物,其中混合物中山梨醇和羟丙基-β-环糊精的重量比为0.5:3;再加入适量的5%羧甲基纤维素钠乙醇溶液制软材,过18目筛制粒,45℃沸腾干燥,备用;
3)向步骤3)中加入适量的硬脂酸钙混合均匀,16目筛整粒,得到干燥的颗粒,备用;
4)将步骤4)干燥的颗粒填充于胶囊壳中,制得首荟通便胶囊。
实施例3:一种首荟通便胶囊,含量及制备工艺如下:
阿胶75重量份、芦荟160重量份、何首乌120重量份、决明子140重量份、枸杞子75重量份、白术50重量份、枳实120重量份、人参50重量份。
制备工艺如下:
a、分提、纯化工艺
1)、将人参、阿胶真空状态下研磨成细粉,过80目筛,备用;
2)、枳实、决明子和白术粉碎并过80目筛,加75%的乙醇回流提取两次,合并滤液,备用;
3)、何首乌、芦荟加水浸泡5小时,用挥发油提取器提取挥发油,药渣及水溶液备用;
4)、取步骤3)中挥发油并用无水硫酸钠干燥,再用处方量的羟丙基-β-环糊精包合,制得包合物;
5)、取3)中蒸馏后的药渣及水溶液与枸杞子加水武火煮沸之后,文火1.5小时,煎煮二次,将两次所得的煎液混合;
6)、将步骤2)的滤液及步骤5)中所得煎液合并,滤过,浓缩至相对密度为1.05的清膏,加乙醇使得醇的含量70%,静止20小时,滤过,减压回收乙醇并浓缩至相对密度的1.35,得稠膏,真空度-0.10Mpa,干燥温度95℃干燥,真空状态下粉碎过80目筛,得细粉,;
7)、将步骤6)中所得细粉、步骤1)中所得细粉、步骤4)中所得挥发油包合物混匀,即得首荟通便提取物,备用;
b、制剂工艺
1)聚乙二醇4000加热熔融,加入处方量的首荟通便提取物拌均匀,40-60℃干燥;
2)测定1)的重量,加入其重量15%的山梨醇和羟丙基-β-环糊精的混合物,其中混合物中山梨醇和羟丙基-β-环糊精的重量比为2.5∶3;再加入适量5%的羧甲基纤维素钠乙醇溶液制软材,过18目筛制粒,55℃沸腾干燥,备用;
3)向步骤3)中加入适量的硬脂酸钙混合均匀,16目筛整粒,得到干燥的颗粒,备用;
4)将步骤4)干燥的颗粒填充于胶囊壳中,制得首荟通便胶囊。
实施例4:一种首荟通便胶囊,含量及制备工艺如下:
阿胶75重量份、芦荟160重量份、何首乌120重量份、决明子140重量份、枸杞子75重量份、白术50重量份、枳实120重量份、人参50重量份。
制备工艺如下:
a、分提、纯化工艺
1)、将人参、阿胶真空状态下研磨成细粉,过80目筛,备用;
2)、枳实、决明子和白术粉碎并过80目筛,加75%的乙醇回流提取两次,合并滤液,备用;
3)、何首乌、芦荟加水浸泡2小时,用挥发油提取器提取挥发油,药渣及水溶液备用;
4)、取3)中挥发油并用无水硫酸钠干燥,再用处方量的羟丙基-β-环糊精包合,制得包合物;
5)、取3)中蒸馏后的药渣及水溶液与枸杞子加水武火煮沸之后,文火1.5小时,煎煮二次,将两次所得的煎液混合;
6)、将2)的滤液及5)中所得煎液合并,滤过,浓缩至相对密度为1.03的清膏,加乙醇使得醇的含量60%,静止15小时,滤过,减压回收乙醇并浓缩至相对密度的1.25,得稠膏,真空度-0.08MPa--0.10Mpa,干燥温度85℃-95℃干燥,真空状态下粉碎过80目筛,得细粉;
7)、将步骤6)中所得细粉、步骤1)中所得细粉、步骤4)中所得挥发油包合物混匀,即得首荟通便提取物,备用;
b、制剂工艺
1)聚乙二醇4000加热熔融,加入处方量的首荟通便提取物拌均匀,50℃干燥;
2)测定1)的重量,加入其重量10%的羟丙基-β-环糊精的混合物,再加入适量5%的羧甲基纤维素钠乙醇溶液制软材,过18目筛制粒,50℃沸腾干燥,备用;
3)向步骤3)中加入适量的硬脂酸镁混合均匀,16目筛整粒,得到干燥的颗粒,备用;
4)将步骤4)干燥的颗粒填充于胶囊壳中,制得首荟通便胶囊。
对比实施例1:一种首荟通便胶囊,含量及制备工艺如下:
阿胶75重量份、芦荟160重量份、何首乌120重量份、决明子140重量份、枸杞子75重量份、白术50重量份、枳实120重量份、人参50重量份。
制备工艺如下:
a、分提、纯化工艺
1)、将人参、阿胶真空状态下研磨成细粉,过80目筛,备用;
2)、枳实、决明子和白术粉碎并过80目筛,加75%的乙醇回流提取两次,合并滤液,备用;
3)、何首乌、芦荟加水浸泡2小时,滤液以及药渣备用;
4)、步骤3)中蒸馏后的药渣与枸杞子加水武火煮沸之后,文火1.5小时,煎煮二次,将两次所得的煎液混合;
6)、将步骤2)、步骤3)的滤液及步骤5)中所得煎液合并,滤过,浓缩至相对密度为1.03的清膏,加乙醇使得醇的含量60%,静止15小时,滤过,减压回收乙醇并浓缩至相对密度的1.25,得稠膏,真空度-0.08MPa--0.10Mpa,干燥温度85℃-95℃干燥,真空状态下粉碎过80目筛,得细粉;
7)、将步骤6)中所得细粉、步骤1)中所得细粉、步骤4)中所得挥发油包合物混匀,即得首荟通便提取物,备用;
b、制剂工艺同实施例1。
对比实施例2:一种首荟通便胶囊,含量及制备工艺如下:
阿胶75重量份、芦荟160重量份、何首乌120重量份、决明子140重量份、枸杞子75重量份、白术50重量份、枳实120重量份、人参50重量份。
制备工艺如下:
a、分提、纯化工艺
1)、将人参、阿胶真空状态下研磨成细粉,过80目筛,备用;
2)、枳实、决明子和白术粉碎并过80目筛,加75%的乙醇回流提取两次,合并滤液,备用;
3)、何首乌、芦荟加水浸泡2小时,用挥发油提取器提取挥发油,药渣及水溶液备用;
4)、取3)中挥发油并用无水硫酸钠干燥,再用处方量的羟丙基-β-环糊精包合,制得包合物;
5)、取3)中蒸馏后的药渣及水溶液与枸杞子加水武火煮沸之后,文火1.5小时,煎煮二次,将两次所得的煎液混合;
6)、将2)的滤液及5)中所得煎液合并,滤过,浓缩至相对密度为1.03的清膏,加乙醇使得醇的含量60%,静止15小时,滤过,减压回收乙醇并浓缩至相对密度的1.25,得稠膏,真空度-0.08MPa--0.10Mpa,干燥温度85℃-95℃干燥,真空状态下粉碎过80目筛,得细粉;
7)、将步骤6)中所得细粉、步骤1)中所得细粉、步骤4)中所得挥发油包合物混匀,即得首荟通便提取物,备用;
b、制剂工艺
1)取首荟通便提取物并加入其重量10%的山梨醇和羟丙基-β-环糊精的混合物,其中混合物中山梨醇和羟丙基-β-环糊精的重量比为1∶2;再加入适量5%的羧甲基纤维素钠乙醇溶液制软材,过18目筛制粒,50℃沸腾干燥,备用;
2)向步骤(1)中加入适量的硬脂酸钙混合均匀,16目筛整粒,得到干燥的颗粒,备用;
3)将步骤(2)干燥的颗粒填充于胶囊壳中,制得首荟通便胶囊。
对比实施例3:一种首荟通便胶囊,含量及制备工艺如下:
阿胶75重量份、芦荟160重量份、何首乌120重量份、决明子140重量份、枸杞子75重量份、白术50重量份、枳实120重量份、人参50重量份。
制备工艺如下:
a、分提、纯化工艺
1)、将人参、阿胶真空状态下研磨成细粉,过80目筛,备用;
2)、枳实、决明子和白术粉碎并过80目筛,加75%的乙醇回流提取两次,合并滤液,备用;
3)、何首乌、芦荟加水浸泡2小时,用挥发油提取器提取挥发油,药渣及水溶液备用;
4)、取3)中挥发油并用无水硫酸钠干燥,再用处方量的羟丙基-β-环糊精包合,制得包合物;
5)、取3)中蒸馏后的药渣及水溶液与枸杞子加水武火煮沸之后,文火1.5小时,煎煮二次,将两次所得的煎液混合;
6)、将2)的滤液及5)中所得煎液合并,滤过,浓缩至相对密度为1.03的清膏,加乙醇使得醇的含量60%,静止15小时,滤过,减压回收乙醇并浓缩至相对密度的1.25,得稠膏,真空度-0.08MPa--0.10Mpa,干燥温度85℃-95℃干燥,真空状态下粉碎过80目筛,得细粉;
7)、将步骤6)中所得细粉、步骤1)中所得细粉、步骤4)中所得挥发油包合物混匀,即得首荟通便提取物,备用;
b、制剂工艺
1)聚乙二醇4000加热熔融,加入处方量的首荟通便提取物拌均匀,50℃干燥;
2)测定1)的重量,加入其重量10%的微晶纤维素和硬脂酸钙的混合物,其中混合物中微晶纤维素和硬脂酸钙1∶2;再加入适量5%的羧甲基纤维素钠乙醇溶液制软材,过18目筛制粒,50℃沸腾干燥,备用;
3)向步骤3)中加入适量的硬脂酸钙混合均匀,16目筛整粒,得到干燥的颗粒,备用;
4)将步骤4)干燥的颗粒填充于胶囊壳中,制得首荟通便胶囊。
对比实施例4:一种首荟通便胶囊,含量及制备工艺如下:
阿胶75重量份、芦荟160重量份、何首乌120重量份、决明子140重量份、枸杞子75重量份、白术50重量份、枳实120重量份、人参50重量份。
制备工艺如下:
a、分提、纯化工艺
1)、将枳实、决明子、枸杞子、人参、阿胶研磨成细粉,过80目筛加75%的乙醇回流提取两次,合并滤液,备用;
2)、何首乌、芦荟、白术加水浸泡2小时武火煮沸之后,文火1.5小时,煎煮二次,将两次所得的煎液混合;
3)、将1)的滤液及2)中所得煎液合并,滤过,浓缩至相对密度为1.03的清膏,加乙醇使得醇的含量60%,静止15小时,滤过,减压回收乙醇并浓缩至相对密度的1.25,得稠膏,真空度-0.08MPa--0.10Mpa,干燥温度85℃-95℃干燥,真空状态下粉碎过80目筛,得首荟通便提取物;
b、制剂工艺
1)取首荟通便提取物并加入其重量10%的山梨醇和羟丙基-β-环糊精的混合物,其中混合物中山梨醇和羟丙基-β-环糊精的重量比为1∶2;再加入适量5%的羧甲基纤维素钠乙醇溶液制软材,过18目筛制粒,50℃沸腾干燥,备用;
2)向步骤(1)中加入适量的硬脂酸钙混合均匀,16目筛整粒,得到干燥的颗粒,备用;
3)将步骤(2)干燥的颗粒填充于胶囊壳中,制得首荟通便胶囊。
对比实施例5:一种首荟通便胶囊,含量及制备工艺如下:
阿胶75重量份、芦荟160重量份、何首乌120重量份、决明子140重量份、枸杞子75重量份、白术50重量份、枳实120重量份、人参50重量份。
制备工艺如下:
(1)将处方量的阿胶研磨过80目筛得细粉,备用;
(2)按配比称取人参、何首乌、决明子、芦荟加60%的乙醇回流两次,第一次10倍,第二次8倍,每次2小时,过滤合并滤液;
(3)枸杞子、白术、枳实加入12倍量水浸泡1.5小时,武火煎煮沸腾15分钟,滤渣加入6倍量水,武火煎煮沸腾之后文火煎煮1.5小时,合并滤液浓缩至相对密度为1.03的清膏,加乙醇使得醇的含量60%,静止24小时,滤过,减压回收乙醇并浓缩至相对密度的1.25,得稠膏,干燥加入阿胶粉和糊精适量,混匀,干法制粒,装入胶囊。
验证实施例:
(一)分散均匀性、崩解时限、含水量及长期性检测的试验
实施例1-4和对比实施例1-5制备的首荟通便胶囊,进行分散均匀性、崩解时限、含水量及长期性检测的试验,具体结果见表1。
含水量的测定方法:采用烘干法计算胶囊的含水量。
分散均匀性的检测方法:将实施例1-6和对比实施例1-4制备的胶囊剂各取2粒,将内部颗粒置于20℃±1℃的100mL水中,振摇3min,过2号药筛。
崩解时限检测方法:将实施例1-6和对比实施例1-4制备的胶囊剂各取6粒,在温度为37℃±1℃的水中,利用升降式片剂崩解仪进行检测。
长期性检测:在温度25℃±2℃、相对湿度60%±10%的条件下放置36个月,然后进行性能检测。
表1各组胶囊进行生化性指标测定结果
从表1可以看出,本发明所述的首荟通便胶囊,崩解效果较好,能在规定的时间的内崩解完成(药典规定30分钟崩解完全),尤其是实施例1的各项指标优于对比实施例。对比实施例1没有制备成包合物,指标较差,对比实施例2没有聚乙二醇,均匀性较差;对比实施例3辅料改变之后,吸水率明显增加,不宜长时间存储,对比实施例4的工艺完全不同于本发明,各项指标低于本发明,不是本发明的处方,长期稳定试验中,崩解时限明显延长,含水量明显增加,不符合中国药典关于胶囊剂崩解时限的要求,含水量也接近临界值,同样不能达到本发明的技术效果;对比实施例5为首荟通便原始制备工艺,虽然符合药典的各项指标,但是效果略低于本发明。
(二)溶出试验
溶出度测定
本发明实施例1-4、对比实施例1-4以及首荟通便胶囊(鲁南厚普制药有限公司,规格:6粒/板×4板/盒,批号:18180041)按照溶出度测定法(《中国药典》2015年版四部通则0931第三法)于200ml蒸馏水为溶出介质、水浴温度为37℃±0.5℃、转速100r·min-1的条件下进行体外溶出试验,以2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷含量为指标进行考察,(2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷含量>1.5mg/粒)。
色谱条件 以十八烷基硅烷键合硅胶为填充剂,以乙腈∶水=32∶68(建议乙腈∶水=22∶78,否则实际操作做不出来)为流动相,VWD(可变波长紫外检测器)检测器。
对照品溶液的制备 取2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷对照品适量,精密称定,加甲醇制成每1ml含0.2mg的溶液,即得。
供试品溶液的制备 取各时间点样品5ml,同时补加5ml的同温蒸馏水,样品经0.45μm微孔滤膜滤过,取2ml续滤液,用水饱和的正丁醇振摇提取4次,每次15ml,合并正丁醇提取液,用浓氨试液洗涤2次,每次20ml,静置30分钟,弃去洗涤液,正丁醇液回收溶剂至干,残渣加甲醇溶解,并转移至2ml量瓶中,加甲醇至刻度,摇匀,滤过,取续滤液,即得。
测定法 取标准溶液,样品溶液,分别进样20ul,采用外标两点法对数方程计算样品中2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷的含量,计算各时间点2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷的累积百分率,结果见表1。表2.不同样品累积溶出百分率(以2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷计)
表2累积溶出百分率(%)
由上表可以看出实施例1-4均达到了80%以上的溶出,20min内均达到了90%以上的溶出,尤其是实施例1优于其他实施例以及对照组;但是对比实施例1没有进行包合物的包合,溶出较低,对比实施例2没有进行的聚乙二醇作为熔融液,溶出也较慢,在15min溶出仅仅为71%,对照品在15min也仅有71.57%,可见,与传统的首荟通便胶囊相比较,本发明首荟通便制剂溶出迅速、全面,说明所制体外溶出效果良好。
长期性检测:在温度25℃±2℃、相对湿度60%±10%的条件下放置36个月,然后进行性能检测。实施例各组变化不大,对比实施例1-4变化较大,对比实施例1和,30min内的溶出低于80%,对比实施例2的杂质含量也较高,但对照品依然符合药典的要求。
Claims (4)
1.一种首荟通便胶囊的制备工艺,其特征在于,所述的制备工艺包含如下步骤:
a、分提、纯化工艺
1)、人参、阿胶真空状态下研磨成细粉;
2)、枳实、决明子和白术粉碎并过80目筛,加65-75%的乙醇回流提取两次,合并滤液,备用;
3)、何首乌、芦荟加水浸泡0.5-5小时,提取挥发油,加入羟丙基-β-环糊精制备包合物,药渣及水溶液备用;
4)、步骤3)的药渣及水溶液与枸杞子加水煎煮,得煎液;
5)、将步骤2)的滤液及4)中所得煎液合并,滤过,浓缩至相对密度为1.01-1.05的清膏,加乙醇使得醇的含量50-70%,静置10-20小时,滤过,减压回收乙醇并浓缩至相对密度1.15-1.35,得稠膏,真空度-0.08MPa——0.10 MPa,干燥温度85℃-95℃,真空状态下粉碎过80目筛,得细粉;
6)、将步骤5)和步骤1)中所得细粉与步骤3)中所得包合物混匀,即得首荟通便提取物;
b、制剂工艺
1)聚乙二醇4000加热熔融,加入首荟通便提取物拌匀,干燥;
2)、向步骤1)中加入填充剂、粘合剂和润滑剂,制粒,干燥,并填充于胶囊壳中,制得首荟通便胶囊;
其中,所述的填充剂为山梨醇和羟丙基-β-环糊精的混合物,所述的粘合剂为羧甲基纤维素钠5%的乙醇溶液,所述的润滑剂为硬脂酸钙;山梨醇和羟丙基-β-环糊精的重量用量比为0.5-2.5:3;所述的阿胶20-180重量份、芦荟40-400重量份、决明子40-250重量份、何首乌25-400重量份、枸杞子30-100重量份、白术10-80重量份、枳实40-280重量份、人参20-100重量份。
2.如权利要求1所述的制备工艺,其特征在于,所述的山梨醇和羟丙基-β-环糊精的重量用量比为1.5:3。
3.如权利要求1所述的制备工艺,其特征在于,所述的制备工艺包含如下步骤:
a、分提、纯化工艺
1)、将人参、阿胶真空状态下研磨成细粉,过80目筛,备用;
2)、枳实、决明子和白术粉碎并过80目筛,加65-75%的乙醇回流提取两次,合并滤液,备用;
3)、何首乌、芦荟加水浸泡0.5-5小时,用挥发油提取器提取挥发油,药渣及水溶液备用;
4)、取步骤3)中挥发油用无水硫酸钠干燥,再用处方量的羟丙基-β-环糊精包合,制得包合物;
5)、取步骤3)中蒸馏后的药渣及水溶液与枸杞子加水煎煮二次,将两次所得的煎液混合,备用;
6)、将步骤2)的滤液及5)中所得煎液合并,滤过,浓缩至相对密度为1.01-1.05的清膏,加乙醇使得醇的含量50-70%,静置10-20小时,滤过,减压回收乙醇并浓缩至相对密度1.15-1.35,得稠膏,真空度-0.08MPa——0.10 MPa,干燥温度85℃-95℃,真空状态下粉碎过80目筛,得细粉;
7)、将1)中所得细粉、4)中所得挥发油包合物、6)中所得细粉混匀,即得首荟通便提取物,备用;
b、制剂工艺
1)聚乙二醇4000加热熔融,加入处方量的首荟通便提取物拌匀,40-60℃干燥;
2)测定步骤1)的重量,加入其重量5-15%的山梨醇和羟丙基-β-环糊精的混合物,其中混合物中山梨醇和羟丙基-β-环糊精的重量比为0.5-2.5:3,再加入适量的羧甲基纤维素钠5%的乙醇溶液制作软材,过18目筛制粒,45-55℃沸腾干燥,备用;
3)向步骤2)中加入适量的硬脂酸钙混合均匀,16目筛整粒,得到干燥得颗粒,备用;
4)将步骤3)干燥得颗粒填充于胶囊壳中,制得首荟通便胶囊。
4.如权利要求3所述的制备工艺,其特征在于,所述的制备工艺包含如下步骤:
a、分提、纯化工艺
1)、将人参、阿胶真空状态下研磨成细粉,过80目筛,备用;
2)、枳实、决明子和白术粉碎并过80目筛,加75%的乙醇回流提取两次,合并滤液,备用;
3)、何首乌、芦荟加水浸泡2小时,用挥发油提取器提取挥发油,药渣及水溶液备用;
4)、取步骤3)中挥发油用无水硫酸钠干燥,再用处方量的羟丙基-β-环糊精包合,制得包合物;
5)、取步骤3)中蒸馏后的药渣及水溶液与枸杞子加水武火煮沸之后,文火1.5小时,煎煮二次,将两次所得的煎液混合,备用;
6)、将步骤2)的滤液及5)中所得煎液合并,滤过,浓缩至相对密度为1.03的清膏,加乙醇使得醇的含量60%,静置15小时,滤过,减压回收乙醇并浓缩至相对密度1.25,得稠膏,真空度-0.08MPa——0.10 MPa,干燥温度85℃-95℃,真空状态下粉碎过80目筛,得细粉;
7)、将1)中所得细粉、4)中所得挥发油包合物、6)中所得细粉混匀,即得首荟通便提取物,备用;
b、制剂工艺
1)聚乙二醇4000加热熔融,加入处方量的首荟通便提取物拌匀,50℃干燥;
2)测定步骤1)的重量,加入其重量10%的山梨醇和羟丙基-β-环糊精的混合物,其中混合物中山梨醇和羟丙基-β-环糊精的重量比为1:2,再加入适量的羧甲基纤维素钠5%的乙醇溶液制作软材,过18目筛制粒,50℃沸腾干燥,备用;
3)向步骤2)中加入适量的硬脂酸钙混合均匀,16目筛整粒,得到干燥得颗粒,备用;
4)将步骤3)干燥得颗粒填充于胶囊壳中,制得首荟通便胶囊。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811404355.1A CN109464570B (zh) | 2018-11-23 | 2018-11-23 | 一种首荟通便胶囊制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811404355.1A CN109464570B (zh) | 2018-11-23 | 2018-11-23 | 一种首荟通便胶囊制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109464570A CN109464570A (zh) | 2019-03-15 |
CN109464570B true CN109464570B (zh) | 2022-06-14 |
Family
ID=65673122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811404355.1A Active CN109464570B (zh) | 2018-11-23 | 2018-11-23 | 一种首荟通便胶囊制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109464570B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112336799B (zh) * | 2019-08-09 | 2023-08-08 | 鲁南制药集团股份有限公司 | 一种中药组合物的新用途 |
WO2021051262A1 (zh) * | 2019-09-17 | 2021-03-25 | 鲁南制药集团股份有限公司 | 一种用于制备治疗水肿药物的中药组合物 |
CN112826887B (zh) * | 2019-11-01 | 2023-06-16 | 鲁南制药集团股份有限公司 | 一种中药组合物在制备咳嗽防治药物中的用途 |
CN112755108A (zh) * | 2019-11-01 | 2021-05-07 | 鲁南制药集团股份有限公司 | 一种中药组合物在制备呼吸系统炎症防治药物中的用途 |
CN111375019A (zh) * | 2020-03-20 | 2020-07-07 | 鲁南制药集团股份有限公司 | 一种首荟通便微囊制剂及其制备方法 |
CN111346158A (zh) * | 2020-04-25 | 2020-06-30 | 鲁南制药集团股份有限公司 | 一种中药组合物在治疗胃肠功能紊乱中的用途 |
CN111437333A (zh) * | 2020-05-09 | 2020-07-24 | 鲁南制药集团股份有限公司 | 一种中药组合物在治疗精神障碍中的用途 |
CN114522204B (zh) * | 2020-10-30 | 2025-02-25 | 鲁南制药集团股份有限公司 | 一种中药组合物在治疗耳鸣中的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1513498A (zh) * | 2003-06-25 | 2004-07-21 | 毛友昌 | 金匮肾气胶囊及制备方法 |
CN1748765A (zh) * | 2004-09-17 | 2006-03-22 | 鲁南制药集团股份有限公司 | 一种具有通便排毒、减肥降脂功能的组合物及制备方法 |
-
2018
- 2018-11-23 CN CN201811404355.1A patent/CN109464570B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1513498A (zh) * | 2003-06-25 | 2004-07-21 | 毛友昌 | 金匮肾气胶囊及制备方法 |
CN1748765A (zh) * | 2004-09-17 | 2006-03-22 | 鲁南制药集团股份有限公司 | 一种具有通便排毒、减肥降脂功能的组合物及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN109464570A (zh) | 2019-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109464570B (zh) | 一种首荟通便胶囊制备工艺 | |
CN111298005A (zh) | 首荟通便胶囊的用途及其制备工艺 | |
CN104758736A (zh) | 一种降糖中药组合物及其制备方法 | |
CN104127738A (zh) | 一种治疗痰热郁肺型支气管扩张的中药及制备方法 | |
CN113713039A (zh) | 一种治疗膜性肾病的中药组合物及其应用 | |
CN105012669A (zh) | 一种治疗上消化道出血的药物及其制备方法 | |
CN109331097B (zh) | 一种化滞柔肝颗粒及其制备工艺 | |
CN1315504C (zh) | 治疗功能性消化不良的提取物及其药物组合物 | |
CN115337365A (zh) | 一种调理肾功能的保健茶及制备方法 | |
CN118976085A (zh) | 一种用于治疗肺癌的中药组合物及其制备方法与用途 | |
CN113599471A (zh) | 一种用于原发性肺癌的中药颗粒及其生产工艺 | |
CN106975050B (zh) | 用于治疗虚劳癥积所致白血病的中药复方制剂及制备方法 | |
CN110960646A (zh) | 一种孕康口服液的制备方法 | |
CN103463601B (zh) | 治疗脾肾阳虚型慢性支气管炎的中药制剂及制备方法 | |
CN117045764B (zh) | 一种用于治疗ii型糖尿病的中药组合物及其制备方法 | |
CN108498466B (zh) | 中药颗粒剂制备工艺及其制备得到的中药颗粒剂 | |
CN114028493B (zh) | 一种用于下肢静脉曲张的药食同源覆红颗粒及其制备方法 | |
CN110327428B (zh) | 一种天麻健脑颗粒及其制备方法 | |
CN108815357B (zh) | 一种具有解热作用的中药组合物及其制备方法 | |
CN108543038B (zh) | 一种化瘀止血的中药组合物及其制备方法和应用 | |
CN107469014A (zh) | 一种治疗女性乳腺增生疾病的药物组合物及其制备方法 | |
CN107753589B (zh) | 一种治疗糖尿病的中药组合物及其制备工艺 | |
CN104524044A (zh) | 一种脂欣康的制备方法 | |
CN116077586A (zh) | 一种斛参增免的药物组合物及其制备方法和应用 | |
CN105770189A (zh) | 一种水果味小儿感冒泡腾颗粒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Liang Shuxia Inventor after: Cheng Guoliang Inventor after: Yang Benguan Inventor after: Zi Li Inventor before: Cheng Guoliang Inventor before: Yang Benguan |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |